Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04309968

Recruitment Status : Unknown

Verified March 2020 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Recruitment status was: Recruiting

First Posted : March 17, 2020

Last Update Posted : June 9, 2020

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	December 31, 2022
Estimated Study Completion Date :	June 30, 2023

To Top